5

## What Is Claimed Is:

- A peptide of eight to twenty amino acids in
- 2 length which comprises a hydrophilic analog of an alpha-
- 3 fetoprotein peptide having SEQ ID NO:6: EMTPVNPG.
- The peptide of claim 1 wherein the peptide is
  linear.
- 1 3. The peptide of claim 1 wherein the peptide is 2 cyclic.
- 1 4. The peptide of claim 1 wherein one or more of 2 the amino acids is a (D)-amino acid.
- 1 5. The peptide of claim 1 which comprises an amino
- 4 SEO ID NO:3: OMTPVNPGE
  - SEO ID NO:4: EMTOVNOG
- 6 SEQ ID NO:5: EMTOVNOGQ
- 7 SEQ ID NO:7: EMTPVNPGQ
- 8 SEQ ID NO:8: EMTOVNPG
- 9 SEQ ID NO:9: EMTOVNPGO
- 10 SEQ ID NO:10: EMTPVNOG and
- 11 SEQ ID NO:11: EMTPVNOGQ,
- 12 or a peptidomimetic of said peptide.
  - 1 6. The peptide of claim 1 labeled with a
  - 2 detectable marker.
  - The peptide of claim 6 wherein the detectable
  - 2 marker is a radiolabel.

- 1 8. The peptide of claim 7 wherein the radiolabel
- 2 is a radiolabeled additional amino acid.
- 1 9. A dimeric peptide consisting of two peptides of 2 claim 1.
- 1 10. The dimeric peptide of claim 9 wherein the two 2 peptides are SEQ ID NO:4 and SEQ ID NO:5.
- 1 11. The dimeric peptide of claim 9,wherein the two 2 peptides are SEQ ID NO:3 and SEQ ID NO:10.
- 1 12. A multimeric peptide consisting of three or 2 more peptides of claim 1.
- 1 13. A composition comprising the peptide of claim  $\mbox{1}$  2 and a suitable carrier.
- 1 14. The composition of claim 13 wherein the
- 2 suitable carrier includes a stabilization excipient.
- 1 15. The composition of claim 14 wherein the 2 stabilization excipient is dodecyl maltoside or mannitol.
- 1 16. An antibody that specifically binds to the
- 2 peptide of claim 1.
- 1 17. A method of reducing estrogen-stimulated growth
- 2 of cells, the method comprising exposing cells to the
- 3 peptide of claim 1.
- 1 18. The method of claim 17 which further comprises
- 2 exposing the cells to tamoxifen before, during, or after
- 3 exposing the cells to the peptide.

- 1 19. A method of treating or preventing cancer in a
- 2 subject which comprises administering to the subject an
- 3 amount of the peptide of claim 1 effective to treat or
- 4 prevent cancer in the subject.
- 1 20. The method of claim 19 wherein the cancer is 2 estrogen-dependent cancer.
- 1 21. The method of claim 20 wherein the estrogen-2 dependent cancer is breast cancer.
- 1 22. The method of claim 19 which further comprises
- 2 administering a suitable amount of tamoxifen to the
- 3 subject before, during, or after administering the
- 4 peptide to the subject.